Med. praxi. 2025;22(3):196-201 | DOI: 10.36290/med.2025.032

Sucrosomial iron - a new way to address iron deficiency

PharmDr. Marek Lapka, Ph.D.
Ústav farmakologie 3. LF UK, Praha

Iron deficiency (ID) is one of the most common nutritional deficiencies worldwide, often leading to anemia and other health complications. Traditional oral iron supplementation using ferrous and ferric salts is associated with low bioavailability and gastrointestinal side effects, limiting patient adherence to treatment. Sucrosomial iron (SI) represents an innovative form of oral iron with improved pharmacokinetic properties, higher tolerability, and better absorption. This article provides a comprehensive review of preclinical and clinical studies evaluating the efficacy and safety of SI in various clinical settings, including pregnancy, oncology, nephrology, and gastroenterology. SI may be an effective alternative to intravenous iron and offers a new option for patients intolerant to conventional oral iron supplements.

Keywords: iron deficiency, anemia, sucrosomial iron, oral supplementation, pharmacokinetics, bioavailability.

Received: April 2, 2025; Revised: April 17, 2025; Accepted: April 29, 2025; Published: June 26, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lapka M. Sucrosomial iron - a new way to address iron deficiency. Med. praxi. 2025;22(3):196-201. doi: 10.36290/med.2025.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. . GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi: 10.1016/S0140-6736(17)32647-8. PMID: 28919117; PMCID: PMC5605509. Go to original source... Go to PubMed...
    2. . Gómez Ramírez S, Remacha Sevilla ÁF, Muñoz Gómez M. Anaemia in the elderly. Med Clin (Barc). 2017 Dec 7;149(11):496-503. English, Spanish. doi: 10.1016/j.medcli.2017.06.025. Epub 2017 Jul 23. PMID: 28743402. Go to original source... Go to PubMed...
    3. . Muñoz M, Peña-Rosas JP, Robinson S, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus Med. 2018 Feb;28(1):22-39. Go to original source... Go to PubMed...
    4. . Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017 Sep;15(5):422-37.
    5. . Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015 Mar;9(3):211-22. Go to original source... Go to PubMed...
    6. . Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf. 2018 Feb;17(2):149-59. Go to original source... Go to PubMed...
    7. . Tolkien Z, Stecher L, Mander AP, et al. Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis. PLoS One. 2015 Feb 20;10(2):e0117383. Go to original source... Go to PubMed...
    8. . Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-33. Go to original source... Go to PubMed...
    9. . Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005 Oct;118(10):1142-7. Go to original source... Go to PubMed...
    10. . Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015 Oct 22;126(17):1981-9. Go to original source... Go to PubMed...
    11. . Franchini M, Marano G, Mengoli C, et al. Red blood cell transfusion policy: a critical literature review. Blood Transfus. 2017 Jul;15(4):307-17.
    12. . Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA. 2016 Nov 15;316(19):2025-35. Go to original source... Go to PubMed...
    13. . Vaglio S, Gentili S, Marano G, et al. The Italian Regulatory Guidelines for the implementation of Patient Blood Management. Blood Transfus. 2017 Jul;15(4):325-8.
    14. . Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018 Jan;107(1):16-30. Go to original source... Go to PubMed...
    15. . Kiss L, Hellinger É, Pilbat AM, et al. Sucrose esters increase drug penetration, but do not inhibit p-glycoprotein in caco-2 intestinal epithelial cells. J Pharm Sci. 2014 Oct;103(10):3107-19. Go to original source... Go to PubMed...
    16. . Fabiano A, Brilli E, Fogli S, et al. Sucrosomial® iron absorption studied by in vitro and ex-vivo models. Eur J Pharm Sci. 2018 Jan 1;111:425-31. Go to original source... Go to PubMed...
    17. . Brilli E, Romano A, Fabiano A, et al. Sucrosomial Technology Is Able to Promote Ferric Iron Absorption: Pre-Clinical and Clinical Evidences. Blood. 2016 Dec 2;128(22):3618. Go to original source...
    18. . Fabiano A, Brilli E, Mattii L, et al. Ex Vivo and in Vivo Study of Sucrosomial® Iron Intestinal Absorption and Bioavailability. Int J Mol Sci. 2018 Sep 12;19(9):2722. Go to original source... Go to PubMed...
    19. . Tarantino G, Brilli E, Zambito Y, et al. Sucrosomial Iron®: A New Highly Bioavaible Oral Iron Supplement. Blood. 2015 Dec 3;126(23):4561. Go to original source...
    20. . Starzynski R, Szudzik M, Staron R, et al. Comparison of the therapeutical potential of oral Sucrosomial iron and parenteral iron dextran supplementations in neonatal iron deficiency anemia in pigs. Am J Hematol. 2017;92:E286.
    21. . Asperti M, Gryzik M, Brilli E, et al. Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation. Nutrients. 2018 Sep 21;10(10):1349. Go to original source... Go to PubMed...
    22. . Brilli E, Lipinski P, Barnadas R, et al. Sucrosomial Iron Absorption Involve M Cells Interaction. Blood. 2017 Dec 8;130:2217. Go to original source...
    23. . Rishi G, Subramaniam VN. The liver in regulation of iron homeostasis. Am J Physiol Gastrointest Liver Physiol. 2017 Sep 1;313(3):G157-65. Go to original source... Go to PubMed...
    24. . Elli L, Ferretti F, Branchi F, et al. Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study. Nutrients. 2018 Mar 9;10(3):330. Go to original source... Go to PubMed...
    25. . Ciudin A, Simó-Servat O, Balibrea JM, et al. Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinol Diabetes Nutr (Engl Ed). 2018 Jan;65(1):17-20. Go to original source...
    26. . Pisani A, Riccio E, Sabbatini M, et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015 Apr;30(4):645-52. Go to original source... Go to PubMed...
    27. . Mafodda A, Giuffrida D, Prestifilippo A, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25(9):2779-86. Go to original source... Go to PubMed...
    28. . Capra AP, Ferro E, Cannavò L, et al. A child with severe iron-deficiency anemia and a complex TMPRSS6 genotype. Hematology. 2017 Oct;22(9):559-64. Go to original source... Go to PubMed...
    29. . Parisi F, Berti C, Mandò C, et al. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial. J Matern Fetal Neonatal Med. 2017 Aug;30(15):1787-92. Go to original source... Go to PubMed...
    30. . Barni S. 4th Mediterranean Multidisciplinary Course on Iron Anemia April 29th-30th 2016, Madrid, Spain: Back to the future: a new iron era. Expert Review of Hematology. 2016 Sep 30;9(sup1):1-42. Go to original source... Go to PubMed...
    31. . Barni S, Gascòn P, Petrelli F, et al. Position paper on management of iron deficiency in adult cancer patients. Expert Rev Hematol. 2017 Aug;10(8):685-95. Go to original source... Go to PubMed...
    32. . Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a 'Kidney Disease: Improving Global Outcomes' (KDIGO) Controversies Conference. Kidney Int. 2016 Jan;89(1):28-39. Go to original source... Go to PubMed...
    33. . Locatelli F, Mazzaferro S, Yee J. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1269-80. Go to original source... Go to PubMed...
    34. . Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis. 2016 Nov;68(5):677-90. Go to original source... Go to PubMed...
    35. . Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015 Oct;88(4):905-14. Go to original source... Go to PubMed...
    36. . Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005 Oct;16(10):3070-80. Go to original source... Go to PubMed...
    37. . Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-71. Go to original source... Go to PubMed...
    38. . Constante M, Fragoso G, Lupien-Meilleur J, et al. Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-induced Colitis. Inflamm Bowel Dis. 2017 May;23(5):753-66. Go to original source... Go to PubMed...
    39. . Stein J, Aksan A, Farrag K, et al. Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother. 2017 Nov;18(16):1721-37. Go to original source... Go to PubMed...
    40. . Stuklov NI, Basiladze IG, Kovalchuk MS, et al. New options in management of Iron-Deficiency syndromes in Inflammatory Bowel Disease. Experimental and Clinical Gastroenterology. 2019 Feb 20;0(2):143-50. Go to original source...
    41. . Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014 Jan 16;123(3):326-33. Go to original source... Go to PubMed...
    42. . Gómez Ramírez S, Brilli E, Tarantino G, et al. Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. Pharmaceuticals. 2023;16(6):847. Go to original source... Go to PubMed...
    43. . Scardino M, Di Matteo B, Martorelli F, et al. Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® iron supplementation: a quality improvement assessment study. International Orthopaedics (SICOT). 2019 Jan 1;43(1):39-46. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.